Microscopic Colitis Management

Initial Therapy

The American Gastroenterological Association (AGA) strongly recommends budesonide as first-line therapy for microscopic colitis based on moderate-quality evidence, with a recommended initial dose of 9 mg once daily for 8 weeks 1
Patients treated with 9 mg of budesonide daily were more than twice as likely to achieve clinical remission compared to no treatment, with a relative risk of 2.52 and a 95% CI of 1.45–4.4 1
An 8-week initial treatment course is recommended, with a strong preference for budesonide over other treatments including mesalamine, bismuth salicylate, or prednisolone 1

Patients treated with budesonide 9 mg daily were nearly twice as likely to achieve clinical and histological remission compared to mesalamine 3 g daily 1
Topical corticosteroids, such as budesonide, have demonstrated effectiveness in improving clinical symptoms in approximately 75-91% of patients, with histologic improvement occurring in a majority of patients 2
Complete histologic response is seen in about 57% of cases 2
Orodispersible budesonide tablets have shown superior efficacy (73.5-75% maintained remission vs 4.4% with placebo over 48 weeks) 3

For patients who respond to initial therapy, consider discontinuation after 8 weeks and monitor for relapse 1
For patients who relapse after discontinuation, restart budesonide at 6 mg daily for maintenance, taper to the lowest effective dose over time, and consider maintenance for 6-12 months 1
Maintenance therapy should be tailored according to individual response and surveillance of potential side effects, with the high risk of relapse after stopping therapy justifying long-term maintenance treatment 3
Up to two-thirds of patients may require maintenance therapy after initial response, and failure to consider maintenance therapy may result in relapse 1

Bone health monitoring is recommended for patients on maintenance therapy, as prolonged use may affect bone density, and consider osteoporosis prevention and screening 1
Routine endoscopic follow-up is not necessary to assess histological response unless symptoms persist 1
Regular clinical follow-up, periodic endoscopy, and growth monitoring in children are recommended for monitoring 3
Common side effects of budesonide include cough, dysphonia, and oral thrush (candidiasis), as well as esophageal candidiasis, dry mouth, and long-term concerns such as growth suppression in children, adrenal suppression, and bone density effects 4, 5, 2, 3

For patients who fail to respond to budesonide, consider evaluation for coexisting conditions such as celiac disease before switching to alternative therapies 1
Cost considerations are important, as budesonide is expensive, and alternative therapies may be considered if cost is prohibitive, though they are less effective 1
Alternative treatments include dietary therapy, systemic corticosteroids, and esophageal dilation for patients who do not respond to topical corticosteroids 5, 2
Systemic steroids are not recommended for maintenance therapy due to significant adverse effects, and immunomodulators (azathioprine, mercaptopurine) are not currently recommended for maintenance therapy of EoE 3

The dosage of budesonide depends on the condition being treated, age, and formulation, with the following recommended dosages:
Proper administration technique is crucial for efficacy, with the following recommendations: